Ben Fenby

Ben Fenby joins Carrick from AstraZeneca where he worked for the past ten years in a range of scientific and commercial leadership roles spanning medical affairs, global marketing and strategy and R&D. Most recently Ben was responsible for cross-functional programme leadership of several multi-billion-dollar registration and phase IIIb life-cycle management assets in cardiovascular and respiratory medicine.

Ben studied biochemistry at the University of Oxford and obtained his PhD in transcriptional regulation of key development signalling pathways at Edinburgh University medical school.